{"id":3155,"date":"2014-10-24T06:30:00","date_gmt":"2014-10-24T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/"},"modified":"2014-10-24T06:30:00","modified_gmt":"2014-10-24T06:30:00","slug":"fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/","title":{"rendered":"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122"},"content":{"rendered":"<\/p>\n

TREDJE KVARTALET (JUL \u2013 SEP 2014)<\/span><\/span><\/strong><\/p>\n<\/p>\n

\u2022 F\u00f6rs\u00e4ljningen under kvartalet \u00f6kade med 34 procent och uppgick till 22,4 MSEK (16,8).
\u2022 F\u00f6rs\u00e4ljningen av eng\u00e5ngsartiklar under kvartalet \u00f6kade med 25 procent och uppgick till 21,0 MSEK (16,8). Oms\u00e4ttnings\u00f6kningen eng\u00e5ngsartiklar var 18 procent i lokala valutor.
\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 3,4 MSEK (3,8) motsvarande en EBITDA marginal om 15 procent.
\u2022 Nettoresultatet uppgick till 1,5 MSEK (1,6), vilket gav ett resultat per aktie om 0,07 SEK (0,08).
\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 4,3 MSEK (-1,5).
\u2022 Produkter f\u00f6r varm perfusion (STEEN Solution\u2122 och produkter relaterade till anv\u00e4ndningen av XPS\u2122<\/span>) stod f\u00f6r 25 procent (13) av f\u00f6rs\u00e4ljningen av eng\u00e5ngsartiklar.
\u2022 XVIVO har erh\u00e5llit marknadsgodk\u00e4nnande f\u00f6r STEEN Solution\u2122 och XPS\u2122 av FDA, vilket m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122, STEEN Solution\u2122 och tillh\u00f6rande eng\u00e5ngsartiklar i USA.
\u2022 XVIVO Perfusions teckningsoptionsprogram 2014\/2016 riktat till anst\u00e4llda fulltecknades.
\u2022 XVIVO Perfusion genomf\u00f6rde en riktad nyemission om 73 MSEK f\u00f6re emissionskostnader. <\/span><\/span><\/p>\n<\/p>\n

PERIODEN (JAN \u2013 SEP 2014)<\/span><\/span><\/strong><\/p>\n<\/p>\n

\u2022 F\u00f6rs\u00e4ljningen under perioden uppgick till 59,2 MSEK (48,9), motsvarande en \u00f6kning om 21 procent i SEK.
\u2022 F\u00f6rs\u00e4ljningen av eng\u00e5ngsartiklar under perioden \u00f6kade med 18 procent och uppgick till 57,7 MSEK (48,9). Oms\u00e4ttnings\u00f6kningen eng\u00e5ngsartiklar var 14 procent i lokala valutor.
\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 8,3 MSEK (10,0) motsvarande en EBITDA marginal om 14 procent.
\u2022 Nettoresultatet uppgick till 4,1 MSEK (5,7), vilket gav ett resultat per aktie om 0,20 SEK (0,29).
\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 1,7 MSEK (6,4).
\u2022 Produkter f\u00f6r varm perfusion (STEEN Solution\u2122 och produkter relaterade till anv\u00e4ndningen av XPS\u2122<\/span>) stod f\u00f6r 24 procent (14) av f\u00f6rs\u00e4ljningen av eng\u00e5ngsartiklar.
\u2022 XPS\u2122 har erh\u00e5llit CE-m\u00e4rke, vilket m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122 och tillh\u00f6rande eng\u00e5ngsartiklar i Europa.
\u2022 XVIVO har erh\u00e5llit marknadsgodk\u00e4nnande f\u00f6r STEEN Solution\u2122 och XPS\u2122 av FDA, vilket m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122, STEEN Solution\u2122 och tillh\u00f6rande eng\u00e5ngsartiklar i USA.<\/span><\/span><\/p>\n<\/p>\n

TELEFONKONFERENS<\/span><\/span><\/strong><\/p>\n<\/p>\n

VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14:00 fredagen den 24 oktober 2014. Telefon: 08-50692180, ange kod 19023328<\/span><\/span><\/p>\n<\/p>\n

G\u00f6teborg 30 september 2014
<\/span>XVIVO Perfusion AB (publ)
<\/span>Magnus Nilsson, VD<\/span><\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n

Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: christoffer.rosenblad@xvivoperfusion.com<\/a>
F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/a><\/span><\/p>\n

XVIVO Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a024 oktober 2014 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TREDJE KVARTALET (JUL \u2013 SEP 2014) \u2022 F\u00f6rs\u00e4ljningen under kvartalet \u00f6kade med 34 procent och uppgick till 22,4 MSEK (16,8)….<\/p>\n","protected":false},"template":"","class_list":["post-3155","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q3","mfn-news-tag-mfn"],"acf":[],"yoast_head":"\nFORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"TREDJE KVARTALET (JUL \u2013 SEP 2014) \u2022 F\u00f6rs\u00e4ljningen under kvartalet \u00f6kade med 34 procent och uppgick till 22,4 MSEK (16,8)....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\\\/\",\"name\":\"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-10-24T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/","og_locale":"en_US","og_type":"article","og_title":"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122 - XVIVO","og_description":"TREDJE KVARTALET (JUL \u2013 SEP 2014) \u2022 F\u00f6rs\u00e4ljningen under kvartalet \u00f6kade med 34 procent och uppgick till 22,4 MSEK (16,8)....","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/","name":"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-10-24T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/fortsatt-stark-forsaljningstillvaxt-samt-fda-godkannande-for-xps-och-steen-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT SAMT FDA GODK\u00c4NNANDE F\u00d6R XPS\u2122 OCH STEEN SOLUTION\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}